Disease-modifying osteoarthritis drugs (DMOADs) are drugs that act on the tissues involved in canine osteoarthritis (OA) to prevent the progression of structural changes.¹ Adequan Canine is the only FDA-approved DMOAD. It is proven safe and effective in helping restore joint lubrication and renewing the building blocks of healthy cartilage, so it can be most effective. effective when used early in the arthritis disease process when there’s still time to slow down cartilage degradation.²

No.

No, there is no generic version of Adequan Canine. Like their brand-name equivalents, generic drugs must be approved by the FDA. Some canine joint supplements and medical devices are named similarly to the active ingredient in Adequan Canine, but can't make claims to achieve similar results. These products are not equivalent to Adequan Canine. They are not backed by the required scientific testing to be approved by the FDA as a generic drug. As an FDA-approved pharmaceutical product, Adequan Canine has gone through a rigorous scientific approval process and must also be made in a facility that adheres to Good Manufacturing Practices.

Adequan Canine is supplied as 100 mg/mL in a 5 mL preserved multiple dose vial. Each package contains 2 vials.

• The approved label dose of Adequan Canine is 2 mg/lb body weight (0.02 mL/lb or 1 mL/50 lb) by intramuscular injection only, twice weekly for up to 4 weeks (maximum of 8 injections). Repeat the treatment protocol as needed. Do not exceed the recommended dose or therapeutic regimen. Do not mix Adequan Canine with other drugs or solvents.
• Be sure to practice aseptic techniques in withdrawing each dose to decrease the possibility of post-injection bacterial infections. Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe. Use only sterile needles, and use each needle only once. Dispose of spent needles in accordance with all federal, state and local environmental laws.
• Use within 28 days of first puncture and puncture a maximum of 10 times.

The approved label dose of Adequan Canine is 2 mg/lb body weight (0.02 mL/lb or 1 mL per 50 lb) by intramuscular injection only, twice weekly for up to 4 weeks (maximum of 8 injections). Adequan Canine is indicated for the control of the clinical signs of OA, and may be used as needed when clinical signs reoccur.

Intramuscular (IM) administration should be in a major muscle group.

No, there has been no stability testing of Adequan Canine when stored in a syringe and this is not recommended. Each dose should be drawn into a syringe and used immediately.

No, Adequan Canine needs to be stored at 68° to 77° F (20° to 25° C) with excursions permitted to 59° to 86° F (15° to 30° C). Avoid prolonged exposure to temperatures greater or equal to 104° F (40° C).

Yes, Adequan Canine contains a preservative, which allows for multiple punctures of an individual vial. Adequan Canine must be used within 28 days of first puncture and is limited to a maximum puncture of 10 times. Please properly dispose of spent needles in accordance with all federal, state and local environmental laws.

No, syringes are not included with Adequan Canine.

Adequan Canine can be ordered through a wide network of authorized veterinary distributors. Please visit Ordering Information or call American Regent Animal Health at 800-458-0163.

Contact your distributor.

Short-dated or expired Adequan Canine product should be returned to the distributor that originally supplied the product, per their established return policies. Contact your distributor or American Regent Animal Health at 800-458-0163.

Yes, you can contact American Regent Animal Health directly at 800-458-0163. You can also connect with your ARAH sales representative or contact your local distributor.